TY - JOUR
T1 - Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells
T2 - The role of the chromatin structure and AP-1 composition
AU - Finzer, Patrick
AU - Soto, Ubaldo
AU - Delius, Hajo
AU - Patzelt, Andrea
AU - Coy, Johannes F.
AU - Poustka, Annemarie
AU - Zur Hausen, Harald
AU - Rösl, Frank
N1 - Funding Information:
The authors thank Dr Eric Stanbridge (University of Irvine, CA, USA) for providing the somatic cell hybrids. The excellent technical help of Maike Lengert is appreciated. Dr Ubaldo Soto was supported by the Alexander von Humboldt Stiftung. This work was supported by the Concerted Action Contract No BIO4-CT98-0097 of the European Community.
PY - 2000/7/6
Y1 - 2000/7/6
N2 - The expression of the monocyte-chemoattractant-protein-1 (MCP-1) is closely linked with a non-tumorigenic phenotype in somatic cell hybrids made between the human papillomavirus type 18 (HPV 18) positive cervical carcinoma cell line HeLa and normal human fibroblasts. In contrast, MCP-1 transcription is absent in tumorigenic segregants derived from the same hybrids or in parental HeLa cells. Selectivity of MCP-1 transcription, which is regulated at the level of initiation of transcription, is mainly based on differences in the location and extension of DNAse I-hypersensitive regions (DHSR) at both ends of the gene. While TNF-α only moderately increases the sensitivity of pre-existing 5'-DHSRs, a 3'-end DHSR became strongly induced exclusively in non-malignant hybrids. DNA sequencing showed that the 3'-DHSR coincides with an additional AP-1 site located approximately 600 bp downstream of the polyadenylation site. Analyses of AP-1 composition revealed that MCP-1 is only expressed in those cells where jun-family members were mainly heterodimerized with the fos-related protein fra-1. In contrast, in tumorigenic cells the 1:1 ratio between jun and fra-1 is disturbed and the MCP-1 gene is no longer expressed. Hence, alterations in the heterodimerization pattern of AP-1 and its selective accessibility to opened chromatin may represent a novel regulator pathway in the regulation of chemokines in malignant and non-malignant HPV-positive cells.
AB - The expression of the monocyte-chemoattractant-protein-1 (MCP-1) is closely linked with a non-tumorigenic phenotype in somatic cell hybrids made between the human papillomavirus type 18 (HPV 18) positive cervical carcinoma cell line HeLa and normal human fibroblasts. In contrast, MCP-1 transcription is absent in tumorigenic segregants derived from the same hybrids or in parental HeLa cells. Selectivity of MCP-1 transcription, which is regulated at the level of initiation of transcription, is mainly based on differences in the location and extension of DNAse I-hypersensitive regions (DHSR) at both ends of the gene. While TNF-α only moderately increases the sensitivity of pre-existing 5'-DHSRs, a 3'-end DHSR became strongly induced exclusively in non-malignant hybrids. DNA sequencing showed that the 3'-DHSR coincides with an additional AP-1 site located approximately 600 bp downstream of the polyadenylation site. Analyses of AP-1 composition revealed that MCP-1 is only expressed in those cells where jun-family members were mainly heterodimerized with the fos-related protein fra-1. In contrast, in tumorigenic cells the 1:1 ratio between jun and fra-1 is disturbed and the MCP-1 gene is no longer expressed. Hence, alterations in the heterodimerization pattern of AP-1 and its selective accessibility to opened chromatin may represent a novel regulator pathway in the regulation of chemokines in malignant and non-malignant HPV-positive cells.
KW - Cervical cancer
KW - Chemokines
KW - Human papillomaviruses
KW - Somatic cell hybrids
KW - Tumorigenicity
UR - http://www.scopus.com/inward/record.url?scp=0034612598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034612598&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1203643
DO - 10.1038/sj.onc.1203643
M3 - Article
C2 - 10918580
SN - 0950-9232
VL - 19
SP - 3235
EP - 3244
JO - Oncogene
JF - Oncogene
IS - 29
ER -